Inflammation plays a critical role in cystic fibrosis (CF) lung pathology and disease
progression making it an active area of research and important therapeutic target. In this …

Highly-effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator
therapy (HEMT) corrects the underlying molecular defect causing cystic fibrosis (CF) …

Background Cystic fibrosis (CF) is a multisystem disease with progressive deterioration.
Recently, CF transmembrane conductance regulator (CFTR) modulator therapies were …

Previously, we showed that serum and monocytes from patients with CF exhibit an
enhanced NLRP3-inflammasome signature with increased IL-18, IL-1β, caspase-1 activity …

Background Abnormal macrophage function caused by dysfunctional cystic fibrosis
transmembrane conductance regulator (CFTR) is a critical contributor to chronic airway …

Despite the addition of cystic fibrosis transmembrane conductance regulator (CFTR)
modulators to the cystic fibrosis (CF) treatment regimen, patients with CF continue to suffer …

Background Cystic fibrosis (CF), which is caused by mutations in the CF transmembrane
conductance regulator (CFTR), is characterised by chronic bacterial lung infection and …

Macrophage dysfunction has been well-described in Cystic Fibrosis (CF) and may contribute
to bacterial persistence in the lung. Whether CF macrophage dysfunction is related directly …

The arrival of cystic fibrosis transmembrane conductance regulator (CFTR) modulators as a
new class of treatment for cystic fibrosis (CF) in 2012 represented a pivotal advance in …

Cystic fibrosis (CF) is a genetic disease caused by mutations in the CFTR gene. Although
viral respiratory tract infections are, in general, more severe in patients with CF compared …